– USA, CA – CURE Pharmaceutical Holding Corp. (OTC: CURR), a proprietary platform technology company, today announced the addition of Gerald Bagg to its board of directors, bringing the board to five members.
“With the increased prominence of CURE’s wholly-owned subsidiary, The Sera Labs, Inc., and the efforts we are undertaking to grow existing brands as well as develop and acquire new brands in the wellness and beauty space with innovative technology, we are very excited to add Gerald’s knowledge and experience to the Company,” said CEO Nancy Duitch.
About Gerald Bagg
A 45+ year veteran of the advertising industry, Gerald Bagg is best known for pioneering the BRAND RESPONSE advertising approach to campaigns. He is the Chairman and a co-founder of Quigley-Simpson & Heppelwhite, Inc., a more than twenty-year-old full-service advertising agency specializing in strategic planning, marketing, media planning and buying, brand building, and creative development, and production. Quigley-Simpson clients include some of the largest consumer goods companies with some of the most well-known brands in the world including over 60 brands from Proctor & Gamble ie. Beauty (CoverGirl), Health & Wellbeing (Olay Vitamins and Supplements in conjunction with Pharmavite) J.P. Morgan Chase credit card division, which includes the United MileagePlus Card, Sapphire Card, and International Hotel Group (IHG) Card amongst others. Other clients of the agency include and have included NBCUniversal, Tivity Health, Ball Corporation, Philips, SC Johnson, Reckitt Benckiser, VISA, and The Hoover Company, to name a few. Before establishing Quigley-Simpson, Gerald had an extensive advertising and marketing career beginning in 1976. Gerald’s distinguished career has included senior executive positions with major advertising agencies and retailers.
“I’m very excited to join the board, and roll up my sleeves as I use my many years of advertising experience and brand-building background to help the Company develop world-class branding and to introduce and evolve the highly innovative products, technology, and brands they are developing into the marketplace,” said Chairman, Gerald Bagg.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is the pioneering developer of CUREform, a patented drug delivery platform that offers several unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the United States, China, Mexico, Canada, Israel, and other markets in Europe.
For more information : https://www.curepharmaceutical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
